Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Glad to see the breakout on the chart yesterday. LTT!
Great times ahead for the months/years to come.
ICE
Somebody wanted more MRES near the end of today....
MRES
ICE
MRES: M2Bio Sciences Provides Corporate Update
NEWS PROVIDED BY
M2Bio Sciences Food and Beverage (Pty) Ltd
March 01, 2024, 13:29 GMT
Institute of Biomedical Research Corp. (OTCBB:MRES)
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, March 1, 2024 /EINPresswire.com/ -- Institute of Biomedical Research Corporation (OTC PINK: MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK: RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).
The transaction was completed and finalized through a complete share-based settlement, leading to a change in control of Real American Capital Corporation. If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
It has been previously disclosed that MRES's CEO, Jeff Robinson, and CFO, Willem Jonker, have been appointed as the Chairman and Chief Financial Officer of RLAB, respectively.
The MRES organogram:
MRES has several divisions that may, after incubation within MRES, be spun out into their own publicly traded entities:
M2Bio Food and Beverage owns and operates three consumer goods brands: Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span many premium CBD-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa, the company and its brands are positioned in the high-value market segment. To cement its status within this premium market segment, M2Bio is committed to an unwavering standard of excellence, prioritizing procuring and producing superior-quality components. This includes using pharmaceutical-grade CBD extracts, premium-grade coffees, and the finest extra virgin olive oils, ensuring consistent delivery of unparalleled product quality and consumer experience.
In March 2023, the Company signed a distribution agreement with Innovative Holdings Alliance Inc. to distribute the Company’s products in the United States of America. The Company’s products are well suited to the premium markets in the USA.
Furthermore, MRES has established a landmark collaboration with the University of Pretoria and Enterprises University of Pretoria to inaugurate the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research. This initiative is dedicated to AI-driven phytomedicine research, propelling MRES's ongoing investigations into plant-based medicines and leveraging Artificial Intelligence and Machine Learning in drug discovery and forensic science.
The Centre is set to revolutionize the field with its extensive database of over 15,000 endemic African plants, offering a rich resource for AI applications in pharmaceutical research. In an innovative approach, the Centre will also integrate NFTs and digital tokens to make the drug discovery process more accessible and democratic.
M2Biome encompasses the nutritional and educational facets of M2Bio Sciences, focusing on the critical connection between gut health and overall wellness. A growing body of evidence highlights the importance of nurturing the microbiome through lifestyle choices. M2Biome is dedicated to delivering products grounded in scientific research tailored to meet the diverse needs of individuals while maintaining the highest standards of quality and environmental sustainability. Our commitment lies in relentless innovation, aiming to offer advanced solutions for enhanced well-being.
M2Enviro, a leader in biotechnological innovation and environmental stewardship, spearheads advancements in mycelium technology to develop innovative, sustainable products. This division is committed to transforming material science by providing eco-conscious alternatives to conventional, harmful petroleum-based materials prevalent today. In 2023, our efforts led to significant achievements in research and development, resulting in the launch of our pioneering product, Hempcelium™.
M2Sentient delves into the interplay between the human sensory system and mental health. In the realm of human biology, the sensory modalities—visual (sight), auditory (hearing), tactile (touch), gustatory (taste), and olfactory (smell)—serve as the primary interfaces between the external environment and our internal psychological landscape. These sensory channels are not merely conduits for data; they are integral to our cognitive processing, shaping our perception, emotion, and cognition.
In the psychological context, Sentience denotes the capacity for conscious perception and experience. It embodies the ability to undergo subjective experiences, encompassing awareness and responsiveness to the environment. This concept is a cornerstone of human consciousness, deeply intertwined with sensory input and interpretation.
The exploration of sentience and the sensory mechanisms offers a nuanced understanding of their pivotal roles in shaping human behavior and mental health. By investigating how sensory experiences influence psychological states, M2 Sentient aims to unravel the complex dynamics of human consciousness and develop innovative approaches to mental health treatment, emphasizing the profound connection between our sensory experiences and overall psychological well-being.
M2Bio Kids represents the nascent division within MRES, spearheading an innovative endeavor to optimize mental and physical health during the critical developmental period from infancy through early childhood (up to five years of age). Anchored in the advanced confluence of biotechnological research and pediatric health sciences, M2Bio Kids is positioned to transform early childhood development strategies. This initiative adopts an integrative methodology, focusing on dietary and nutritional interventions, physical activities, cognitive exercises, and enhancing critical thinking skills through AI-driven hardware and software applications. This comprehensive approach fosters holistic growth and development in the early years, setting a foundation for lifelong health and well-being.
Real American Capital Corporation (OTC PINK: RLAB) is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "RLAB." https://www.otcmarkets.com/stock/RLAB/.
Contact:
Jeff Robinson, CEO
Jeff@m2bio.co
+27 72 333 2148
MRES: M2Bio Sciences Provides Corporate Update
Friday, 01 March 2024 09:10 AM
ACCESSWIRE | Article Logo
Institute of BioMedical Research Corp.
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK:RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).
The transaction was completed and finalized through a complete share-based settlement, leading to a change in control of Real American Capital Corporation. If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
It has been previously disclosed that MRES's CEO, Jeff Robinson, and CFO, Willem Jonker, have been appointed as the Chairman and Chief Financial Officer of RLAB, respectively.
The MRES organogram
MRES has several divisions that may, after incubation within MRES, be spun out into their own publicly traded entities:
M2Bio Food and Beverage owns and operates three consumer goods brands: Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span many premium CBD-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa, the company and its brands are positioned in the high-value market segment. To cement its status within this premium market segment, M2Bio is committed to an unwavering standard of excellence, prioritizing procuring and producing superior-quality components. This includes using pharmaceutical-grade CBD extracts, premium-grade coffees, and the finest extra virgin olive oils, ensuring consistent delivery of unparalleled product quality and consumer experience.
In March 2023, the Company signed a distribution agreement with Innovative Holdings Alliance Inc. to distribute the Company's products in the United States of America. The Company's products are well suited to the premium markets in the USA.
Furthermore, MRES has established a landmark collaboration with the University of Pretoria and Enterprises University of Pretoria to inaugurate the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research. This initiative is dedicated to AI-driven phytomedicine research, propelling MRES's ongoing investigations into plant-based medicines and leveraging Artificial Intelligence and Machine Learning in drug discovery and forensic science.
The Centre is set to revolutionize the field with its extensive database of over 15,000 endemic African plants, offering a rich resource for AI applications in pharmaceutical research. In an innovative approach, the Centre will also integrate NFTs and digital tokens to make the drug discovery process more accessible and democratic.
M2Biome encompasses the nutritional and educational facets of M2Bio Sciences, focusing on the critical connection between gut health and overall wellness. A growing body of evidence highlights the importance of nurturing the microbiome through lifestyle choices. M2Biome is dedicated to delivering products grounded in scientific research tailored to meet the diverse needs of individuals while maintaining the highest standards of quality and environmental sustainability. Our commitment lies in relentless innovation, aiming to offer advanced solutions for enhanced well-being.
M2Enviro, a leader in biotechnological innovation and environmental stewardship, spearheads advancements in mycelium technology to develop innovative, sustainable products. This division is committed to transforming material science by providing eco-conscious alternatives to conventional, harmful petroleum-based materials prevalent today. In 2023, our efforts led to significant achievements in research and development, resulting in the launch of our pioneering product, Hempcelium™.
M2Sentient delves into the interplay between the human sensory system and mental health. In the realm of human biology, the sensory modalities-visual (sight), auditory (hearing), tactile (touch), gustatory (taste), and olfactory (smell)-serve as the primary interfaces between the external environment and our internal psychological landscape. These sensory channels are not merely conduits for data; they are integral to our cognitive processing, shaping our perception, emotion, and cognition.
In the psychological context, Sentience denotes the capacity for conscious perception and experience. It embodies the ability to undergo subjective experiences, encompassing awareness and responsiveness to the environment. This concept is a cornerstone of human consciousness, deeply intertwined with sensory input and interpretation.
The exploration of sentience and the sensory mechanisms offers a nuanced understanding of their pivotal roles in shaping human behavior and mental health. By investigating how sensory experiences influence psychological states, M2 Sentient aims to unravel the complex dynamics of human consciousness and develop innovative approaches to mental health treatment, emphasizing the profound connection between our sensory experiences and overall psychological well-being.
M2Bio Kids represents the nascent division within MRES, spearheading an innovative endeavor to optimize mental and physical health during the critical developmental period from infancy through early childhood (up to five years of age). Anchored in the advanced confluence of biotechnological research and pediatric health sciences, M2Bio Kids is positioned to transform early childhood development strategies. This initiative adopts an integrative methodology, focusing on dietary and nutritional interventions, physical activities, cognitive exercises, and enhancing critical thinking skills through AI-driven hardware and software applications. This comprehensive approach fosters holistic growth and development in the early years, setting a foundation for lifelong health and well-being.
Real American Capital Corporation (OTC PINK:RLAB) is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "RLAB." https://www.otcmarkets.com/stock/RLAB/.
Contact:
Jeff Robinson, CEO
Jeff@m2bio.co
+27 72 333 2148
MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward ------ Thursday, 22 February 2024 09:15 AM
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edgemental health therapeutic research driven by artificial intelligence (AI), is pleased to sharethe following M2Enviro updates:
M2Enviro, at the forefront of biotechnological innovation and sustainability, is pioneering mycelium technology to engineer groundbreaking, eco-friendly products. This division is dedicated to redefining the landscape of material science, offering sustainable alternatives to the traditional, environmentally detrimental, petroleum-based materials that dominate our world. In 2023, we achieved remarkable breakthroughs in research and development, culminating in the creation of our flagship innovation, Hempcelium™. This avant-garde biodegradable packaging solution, ingeniously combining hemp with mycelium, stands at the vanguard of environmental stewardship. Hempcelium™ has captured the industry's imagination and positioned itself as a formidable challenger to conventional petroleum-based packaging, heralding a new era of sustainable material science.
As M2Enviro propels into the forthcoming year, the guiding principle is exponential growth-reflecting the boundless expansion characteristic of mycelium networks. The company is poised to dramatically extend its influence and augment its operational capabilities, leveraging the substantial foundation laid in the previous year. This strategic expansion is not merely an increase in scale but a profound amplification of our scientific endeavors, underscoring our commitment to redefining the frontiers of biotechnological innovation and sustainability.
In 2024, M2Enviro embarks on an ambitious continuation of its mission, with a reinforced commitment to research & development and the engineering of novel products, with a particular focus on the advancement of Hempcelium™. This commitment to ongoing scientific inquiry guarantees perpetual innovation, upholding the most stringent standards of excellence. As we transitioned out of 2023, Hempcelium™ was subjected to exhaustive performance evaluations, where it exceeded both our internal criteria and established industry benchmarks across multiple measures of strength-affirming our scientific assertions regarding the material's exceptional resilience, durability, and superior quality. This achievement signifies a milestone in material science and reinforces our position at the forefront of sustainable engineering solutions.
This triumph marks a pivotal moment for the industry, heralding a monumental stride towards providing eco-conscious alternatives without sacrificing performance. The outcomes of our rigorous R&D endeavors over the past two years underscore our unwavering dedication to revolutionizing the industry and affirm the viability of Hempcelium™ as a transformative, sustainable packaging solution. This is not merely progress; it is a bold declaration of our capacity to redefine the future of environmental sustainability.
"In 2023, we achieved a significant milestone in developing the inaugural mycelium composite surfboard, with the official release scheduled for March 2024. M2Enviro is accelerating the fabrication of the next three boards, targeting completion by May 2024. Additionally, we are offering six unique, limited-edition boards on M2Bio Science's OpenSea platform as NFTs, showcasing the innovative potential of this project. This initiative goes beyond traditional surfboard manufacturing; it represents a pioneering step in utilizing mycelium technology, setting new standards for sustainable design and engineering in the surf industry," articulated Stephanus Louwskieter, lead R&D Engineer.
M2Enviro is actively engaging with potential clients behind the scenes, with plans to onboard some in 2024. Due to an overwhelming demand for our Hempcelium™ that far exceeds our current production capabilities, we are taking significant steps to address this exciting challenge. An in-house production facility in Hout Bay is under construction, aimed explicitly at scaling production and operations for increased efficiency and product availability. This strategic expansion is critical for meeting the surging interest and ensuring we can fulfill the growing needs of our market. Additionally, the division will launch targeted social media campaigns to raise awareness and showcase the unique features of Hempcelium™. We are also exploring collaborations with local artists to introduce mycelium composite materials through art and culture, further enhancing public awareness and understanding of the material. These initiatives are designed to meet the current demand and solidify our position as leaders in mycelium composite materials' innovation and sustainable use.
Aidan Price, the visionary MD of M2Enviro, exuded unparalleled enthusiasm for the future, proclaiming, "2023 was the year we laid down our roots, setting the stage for what's to come. As we step into 2024, we're not just ready to grow-we're set to redefine the sustainability landscape. Our relentless pursuit of innovative mycelium applications and unwavering dedication to eco-conscious principles place us at the forefront of the movement towards a greener tomorrow."
With an ambitious eye on exponential growth, M2Enviro is passionately committed to transcending the frontiers of sustainable technology, catering to the sophisticated needs of the environmentally aware consumer.
Great summary of 2023 and 2024 objectives.
ICE
Nice call
ICE
Glad to see the volume as we patiently wait for this stock to start it's life!
ICE
Been buying more myself over the days/weeks.
Love a good sale
ICE
"Same. No other CEO in all OTC has a better track record. Yes WUHN was a huge mistake for the CEO, but it happens. I will keep trusting Jeff!"
Make up your mind.
ICE
MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park
--------- OTC DISCLOSURE & NEWS SERVICE Press Release 11/15/2023 ---
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES): A pioneering force in nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and avant-garde mental health therapeutic research driven by artificial intelligence (AI), is delighted to share a significant update:
M2Bio Sciences Embarks on Strategic Expansion into Dubai Science Park
M2Bio Sciences proudly announces its strategic expansion into Dubai Science Park, a vibrant hub of innovation and scientific excellence. Establishing new offices on the thirteenth floor of the Dubai Science Park's South Tower, Dubai, United Arab Emirates, signifies a noteworthy milestone in M2Bio Sciences' commitment to advancing groundbreaking research and development in AI-driven nutraceutical biotechnology and fintech.
Additionally, the company has established its wholly-owned Dubai subsidiary, M2Bio Sciences Research FZ-LLC.
Dubai Science Park, renowned for fostering collaboration and innovation, provides M2Bio Sciences with an ideal environment to amplify its efforts in developing cutting-edge solutions addressing global health challenges. These new offices, positioned at the crossroads of Europe, Asia, and Africa, place M2Bio Sciences at the forefront of the international biotechnology and fintech landscapes.
Establishing a presence in Dubai Science Park aligns with M2Bio Sciences' mission to enhance its global footprint and foster collaboration with diverse partners, scientists, and professionals. This move reflects a commitment to leveraging Dubai's unique ecosystem to drive innovation, accelerate research, and contribute to advancing the biotechnology and fintech industries.
Jeff Robinson, CEO at M2Bio Sciences, expressed enthusiasm about these developments, stating, "We are excited to announce both the opening of our offices in Dubai Science Park, a pivotal step in our journey to expand our global reach, and the incorporation of our Dubai subsidiary. This strategic move enables us to collaborate with world-class talent, access state-of-the-art facilities, and participate in a thriving community of like-minded professionals. We look forward to contributing to the dynamic scientific landscape in Dubai and beyond."
M2Bio Sciences, renowned for its pioneering research into cannabis and psilocybin, has expanded its research and commercialization efforts, focusing on a range of nutraceuticals for mental health, longevity, and cardiometabolic health. The company's sustainability division works on improving environmental health by utilizing mycelia technology to produce biodegradable packaging solutions in the form of Hempcelium™. The presence of M2Bio Sciences in Dubai Science Park will enhance its research capabilities, foster international partnerships, and contribute to developing innovative solutions with the potential to impact lives globally.
"Same. No other CEO in all OTC has a better track record. Yes WUHN was a huge mistake for the CEO, but it happens. I will keep trusting Jeff!"
Very good plan!
ICE
"In addition, M2BIO Sciences proudly announces the appointment of Victor Lange as CEO of M2MMA. Lange, with a rich history in the world of sports, including studying in the US and earning his playing rights on the PGA Tour for several years, has since been deeply involved in the fitness and business world."
Step by step ... NICE!
ICE
"Those comical warnings always seem to send the stock higher. Very impressive volume yesterday. :)"
That seems to be one of the few constants with our stock.
ICE
Great start here today!
ICE
Reminded again today that we were warned. We also know what that triggers .... 2.3 mil so far trading at .0147
Don't gap the open!
STARBUCKS!!!!! Looking forward to the weeks, months, and years to come!
ICE
No moss growing under Jeff's feet!
WOW!
ICE
MRES: M2Bio Sciences Establishes Research Chair at The University of Pretoria for Phytomedicines
NEWS PROVIDED BY
Institute of Biomedical Research Corp.
16 Jun, 2023, 08:52
CAPE TOWN, South Africa, June 16, 2023 /PRNewswire/ -- Institute of Biomedical Research Corp. (OTC PINK: MRES) ("Institute of Biomedical Research" or the "Company"), a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions, is pleased to share the following update:
M2Bio Sciences is delighted to announce it has signed an agreement with the University of Pretoria/Universiteit van Pretoria and Enterprises University of Pretoria to continue research into Plant Medicines, and the application of Artificial Intelligence and Machine Learning to drug discovery and forensic science.
The agreement was cemented with the official signing ceremony on the 12th of May 2023 between Prof Barend Erasmus, Dean of the Faculty of Natural and Agricultural Sciences, Mr. Jeff Robinson, CEO and Chairman of M2Bio Sciences, and Dr. Elmar de Wet, CEO, Enterprises University of Pretoria.
The UP Biodiscovery Centre, led by Prof Vinesh Maharaj, NAS Deputy Dean for Research and Postgraduate Education and a renowned bio-prospector, will conduct commercial natural product research and development. The M2Bio Sciences Research Chair will conduct research focused on science and evidence-backed premium health and wellness products over the next four years.
An integral part of the research is to use Artificial Intelligence (AI) to discover natural product lead compounds that can be developed as pharmaceutical and food ingredients.
"We need to emphasize the value of AI in African research. It is important to digitize the great research and developments on the continent. Although I am not a scientist, I have an enormous passion for science, technology, and medicine and how they intersect," Mr. Jeff Robinson, CEO of M2Bio Sciences stated.
In addition, Robinson believes very strongly that product development must be backed by evidence-based scientific research.
"There is so much potential and talent in South Africa; I am wondering why there are not more companies cooperating with universities to do research," said Mr. Robinson.
Prof Erasmus echoed these sentiments, saying, "There are three important elements of partnerships, especially evident in today's agreement: the nature, aspirations, and the vision of the people involved in this partnership. The three partners, UP/NAS, M2Bio Sciences, and Enterprises UP, responded well to this great opportunity. It is important to note that NAS has many more unique value propositions as our diversity, ranging from the basic sciences to the agricultural sciences, encompasses the whole (agricultural) value chain."
Prof Maharaj added that the partnership brings industry and academia closer and contributes to creating a more significant impact on society through translational and transdisciplinary research.
In his final remarks, Mr. Robinson said that "M2Bio Sciences is very excited to be working with Prof Maharaj with his stellar knowledge – this translational research ties in with the University's transdisciplinary research and is guided by society's needs."
Dr. Elmar de Wet, CEO of UP Enterprises, concluded the event by stating, "The world has more than enough problems, and our scientists, in partnership with industry, can facilitate the solutions and make it happen."
"Much more detail on this agreement and the current research on the go will be released very soon. Stay tuned and keep connecting the dots!" said Robinson.
Chart giving us a little resistance here. Volume will take care of this.
ICE
Jeff is taking communication direct to the shareholders with these daily updates. With execution, sub-pennies will be gone.
ICE
I agree, communication is key for a company to flourish.
ICE
Lawyers and deal making today, love it!
Tomorrow's update with news.... It is nice to hear what is going on regularly with this company.
ICE
M2Bio Appoints Ze-ev Krein as Chairman of the M2Bio Scientific Advisory Board
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, April 6, 2023/EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Ze-ev Krein has accepted the Chairman position for M2Bio’s Scientific Advisory Board. His experience in legislation, drug development, analytical chemistry, and computer science will be invaluable in guiding the board to develop novel approaches to innovation and the pursuit of the discovery of novel bioactive compounds.
Mr. Krein graduated as a University of Cape Town class medallist, with a B Com in Information Systems. He then went on to follow his passion for science and completed his B Sc in chemistry within two years. He completed his honors in chemistry at the University of Stellenbosch (Dissertation: Molecular Lego Self-assembly of new Metallomacrocyclic Complexes of Bi-Podal N-aroyl-N’, N’ -dialkyl thioureas) and his Masters in Medicinal Chemistry at University of Cape Town (UCT) under Prof Dr. Kelly Chibale. His research was in the field of drug development (Dissertation: “Utilisation of efficient reactions to combine moieties exhibiting biological activity to produce novel anti-infectives against HIV and Malaria”). After his Masters, he ran the inorganic/analytical lab for the Forensic Science Laboratory at the South African Police Service (SAPS). During this period he served as an expert witness in high-profile cases and completed his LLB from UNISA. He has also served as the commander of the Cyber Unit for Crime Intelligence and is now a section commander for the South African Narcotics Enforcement Bureau. He has founded multiple technology companies and serves on a number of committees including the Cannabis Working Group with SAHPRA, a decisive group on the legislation of Cannabis.
On the acceptance of his appointment, Mr. Krein had the following to say:
“Health is a holistic approach, the mind, and body need to be a harmonious unit. You cannot assess mental health without considering physiological health. We are in an era where our minds are tossed around like a ping pong ball through online distractions and our physiology is recovering from the bombardment of the sugar era. Health begins with awareness followed by positive behavior and habits. M2Bio Sciences is deeply invested in and committed to this approach. M2Bio places immense focus on providing only the highest quality of nutrient-rich products for the body, and provides exemplary approaches to a healthy lifestyle. Through the products and the environment M2Bio seeks to create, the consumer will experience a genuine increase in their well-being and seek further good behaviors. I was excited to walk this path with M2Bio when I realized their commitment to scientific research and an unwavering commitment to providing the highest quality product. Their holistic approach is visible in their partnership with high-performance athletes and the funding of independent research led by university faculties. I am confident that our path together will not only lead to healthier individuals but also to a happier and more informed society.”
''Having such a brilliant mind join our team at this time in the M2Bio journey is so fortuitous. Zev and I share so much in common in terms of thought processes and critical thinking. We both have a passion for deploying advanced technologies to drive better outcomes for medicine, science, and health. Zev and I will be working very closely to execute some very remarkable deliverables in the coming months. Remember always to connect the dots.'' - said Jeff Robinson, M2Bio Sciences CEO.
M2Bio Sciences Appoints Wilna Eksteen as M2Biome Senior Cardiometabolic Product Developer
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, April 5, 2023/EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
M2Bio Sciences is excited to welcome Wilna Eksteen as the newest addition to its team. Wilna will join as a Cardiometabolic Product Developer within the M2Biome division. In this capacity, Wilna will be responsible for supporting M2Biome in their product and recipe development efforts, as well as creating recipes for the Liviana and Medspresso consumer-facing brands.
Wilna Eksteen is a registered dietitian and a graduate of the University of Pretoria. During her Community Service year at the Steve Biko Academic Tertiary Hospital in Pretoria, she discovered her passion for implementing sensible nutritional practices.
As a foodie, mom of two girls, and practicing dietitian, Wilna has gained substantial experience in how people connect with food, mentally, physically, and emotionally. She has deep experience working in a clinical environment, health product industry, recipe writing, and product development.
Wilna Eksteen grew up in a home where her mom was a dietitian, giving her a head start into having "healthy roots". For her, healthy eating and living were never something to consider, it was just the way life was meant to be. Now, with her special interest in product development and recipe writing, Wilna brings her unique perspective on food to the table. She has a gift for making the most delicious dishes with the fewest ingredients, using the perfect methods, and always with a smile.
Wilna is absolutely passionate about sustainability and how it can be achieved for everyday living. Recycling, reusing, reducing, composting, bokashi, rainwater harvesting, greywater harvesting, worm farms, vegetable gardens, chicken coops, you name it she has tried it.
"The desired outcome cannot be achieved if you dishonor what you put into the process. Put yourself up for success. Health is holistic and everything should be simply nutritious.” said Wilna.
Her goal is to simplify cooking using ‘’clean’’ nutritious ingredients. The dishes will be tasty, beneficial to your well-being, and promote a healthy holistic lifestyle. As a cardiometabolic product developer, she hopes to bring the most amazing and nutritious products for you to enjoy from the comfort of your own home. Educating about facts, having fun, and enjoying food will be the focus.
‘’We are delighted to have Wilna joining the M2bio Sciences team. She brings her impressive credentials and passion for health and nutrition to our mission. With her expertise, we aim to lead the charge in educating people on proper health and wellness practices, and propel M2bio to the forefront of the industry,’’ said Jeff Robinson, CEO M2Bio Sciences.
M2Bio Sciences announces Nicola Royce as M2Biome Managing Director
M2Bio Sciences (OTCBB:MRES)
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, March 14, 2023 /EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
M2Bio Sciences is pleased to announce that Nicola Royce has joined the M2Bio Sciences Team as the M2Biome Managing Director. The M2Biome division relates to all nutrition aspects of M2Bio Sciences and associated education. There is increasing evidence to elucidate the link between the gut and all-things health, and how important it is to optimise the microbiome through lifestyle. The aim of M2Biome is to provide products that meet specific needs of various population groups that are evidence-based, of the highest quality and environmentally sustainable.
An experienced and registered Dietitian, Nicola Royce holds a demonstrated history of working in the health care and health product industry. She has a special interest in diabetes and related comorbidities.
Having grown up on a farm in Zimbabwe, where her family practiced farm-to-fork with their own vegetable garden and livestock, Nicola was exposed to food being ‘medicine’ from a young age. She is passionate about plants and loves collecting interesting species from various places when she travels locally.
Her interest in the sciences, love of food, and obsession with plants serendipitously lead her to study Dietetics, which she completed through the University of Pretoria. Nicola then undertook her Community Service year in Northern Kwa-Zulu Natal, where her eyes were opened to how rife type 2 diabetes is and how poorly this was being managed, sparking her interest in learning more about this condition. Her work experience includes a role at a health food company and a diabetes company. Over the years she has gained skills in researching functional food products, social media, marketing and education content development.
In her own words: “As a result of my experience, I am a strong advocate for the prevention, management, and possible remission of type 2 diabetes.”
Simple. Fresh. Nutritious
This is the key to following a balanced eating plan, and her mantra as a dietitian. She believes that simplifying core nutrition concepts should enable everyone to follow a healthy eating pattern.
“My vision for the M2Biome division is to provide products that improve health, performance, longevity, and quality of life, and that are evidence-based, of the highest quality, and environmentally sustainable. I also aim to provide health education to upskill and empower people to make informed decisions about nutrition and lead a healthy lifestyle” said Nicola Royce.
‘’We are very fortunate to have Nicola on the M2Bio Sciences team and leading up the M2Biome Division. Obesity and Diabetes are rampant and we must find different evidence-based clinical methods to treat those afflicted. The amount of processed foods we consume is insane and deadly. It must stop. Nicola with so much empathy and deep knowledge of the space will without a doubt be making a very big mark in the space.’’ said Jeff Robinson, CEO, M2Bio Sciences.
https://www.einpresswire.com/article/622075236/m2bio-sciences-announces-nicola-royce-as-m2biome-managing-director
M2Bio Sciences Announces New Brand Ambassador:
M2Bio Sciences (OTCBB:MRES)
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, March 15, 2023 /EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
https://www.einpresswire.com/article/622299203/m2bio-sciences-announces-new-brand-ambassador-shadrack-blambee-nsua
Shadrack ‘’Blambee’’ Nsua has joined the growing list of remarkable M2Bio Sciences Brand Ambassadors.
Hailing from the Democratic Republic of Congo, 29-year-old Shadrack “Blambee” Nsua is a Pro MMA fighter out of Port Elizabeth, South Africa and currently the #17th ranked Pro Men's Middleweight in South Africa.
You may have seen his extraordinary win over Mark Kamba at the latest EFC101 by way of Verbal Submission on March 02 2023 at the EFC Peak Performance Institute In Johannesburg, South Africa. His next fight will be at EFC 103 or 104.
Currently 2-0 in the EFC, Shadrack is fighting under PESFA Academy and coach Chris Bright in Port Elizabeth. Coming up from an amateur undefeated record, he looks to build himself in the pro levels and eventually get fights around the world. His dream is to compete with the best in the UFC. As of now he is practicing and perfecting all the fighting disciplines and building his character while managing and running his own fitness apparel and casual wear brand “Blambee Clothing”.
“As a former MMA Amateur Lightweight Champion I know what it takes to win. Hard work, consistency, and so much discipline. I know I’m going to make a mark as a pro MMA fighter as well. My coach Chris is second to none and having the M2Bio Sciences Team behind me is such a big plus.”
‘’Shadrack is technically sound and has incredible hulk-like strength. His latest victory demonstrated just how good he is and how great he will become. Outside the ring, like so many of these great fighters, a gentle giant. We are blessed to have Shadrack on the M2Bio Sciences Team.” said Jeff Robinson, CEO, M2Bio Sciences.
Nice buy(s)!
MRES
ICE
Jeff Robinson, CEO and Chairman of M2bio ????$MRES 8:54 AM · Feb 2, 2023
@contrariansmind
Let's see if anybody can connect the dots. $MRES So many will look back at this moment and say ''If only I..." Coulda, woulda, shoulda folks... ????https://einpresswire.com/article/614126470/m2bio-opens-bangkok-office-and-appoints-managing-director
@m2bio
einpresswire.com
M2Bio Opens Bangkok Office and Appoints Managing Director
Jade M2Bio Thailand Offices
Jade M2Bio Thailand Offices
Institute of Biomedical Research (OTCBB:MRES)
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, February 2, 2023 /EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a biotechnology company focused on alternative plant-based cannabinoids and mental health clinical research is pleased to share the following update:
M2Bio Sciences is pleased to announce the opening of corporate offices in Bangkok, Thailand. The operations are being headed up by the newly appointed Managing Director, Jade Sirisompan. Jade has an MSC in psychology and has been working in the mental health sector for the past two years. Jade also has extensive experience in the Muay Thai and fitness industry as a professional fighter and champion, personal trainer, gym manager and fight promoter. Jade was born and raised in England until the age of 14, then moved to Thailand.
Under the guidance of Jade’s father, Muay Thai legend Chinawut Sirisompan, famously known as Grandmaster Woody, she found a passion for the Martial Arts industry, management, teaching, promotions, and more.
“My past experiences have helped me develop great resilience, social and emotional intelligence, cultural competency, and empathy for people from all walks of life, which have ultimately helped guide me in my profession of counseling psychology.”
‘’The mental wellness sector is continuously evolving and with M2bio Sciences the future looks very bright. They have such impressive clinical evidence-based research and quality premium products, all with the purpose of optimizing health. From the revolutionary mycelium and hemp for packaging, psychedelics for treating mental health issues, and to the finest CBD infused organic honey, coffee, and olive oil for nutritional and peak cognitive functioning.’’
‘’M2bio also supports and is highly engaged in sport, fitness, and entertainment. In collaboration with the EFC MMA Championship, the sport is used to educate and inspire the general public on positive health practices and provide athletes with sponsorship opportunities. The M2Bio vision is expansive and they understand the many areas in which health outcomes can be improved. As someone who is seriously passionate about health, psychology, and helping people improve their quality of life, together with my background in the combat sports industry I am very excited and truly honored to be a part of the m2bio team and to help M2Bio Sciences Thailand come to life.” - Jade Sirisompan, Managing Director of M2Bio Sciences Thailand.
‘’We are truly excited and fortunate to have such a dedicated professional in our corner. Her positive energy is an inspiration for the current and next generation of athletes. The M2Bio and EFC teams are very excited to be working with Jade. And remember, always be connecting the dots’’ - said Jeff Robinson, CEO of M2Bio Sciences.
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES". Publicly traded company (OTC Pink:MRES)
Website: www.m2bio.co
E-mail: info@m2bio.co
Find M2Bio™ on social media
Follow us on Facebook: m2bio.sciences
Follow us on Instagram: M2Bio Sciences
Follow us on LinkedIn: M2Bio Sciences, Inc.
Sorry to see all the moderators that I welcomed just months ago have moved on..... I didn't read anything negative on MRES yet.
This recent press release on 1/19/2023 seems positive - M2Bio Sciences CEO Jeff Robinson - “We are stoked to continue bringing serious science, medicine and technology to the EFC. Our partnership is really something out of this world so you better fasten your seatbelts for 2023 because we’re headed for Uranus! ”
ICE
LFG ... DITTO!
Great to hear news is getting out to many .... Now we just need the right news to start this climb!
MRES
ICE
Huge company being built.
ICE
Great find IAMMINDFULL!
ICE
Strategy and hope ........
ICE
Welcome aboard doogdilinger!
Welcome aboard pmunch!
ICE
Just the beginning here.
Just need some volume to work thru the 1st batch of profit takers from .01
Opening gap at .0185 today..
Slow and steady ....... until it's not!
ICE
I'm counting on it LTT!
ICE